What's in Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.'s pipeline?

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. has 12 drugs in our index: 2 marketed, 0 filed, 7 in Phase 3, 0 in Phase 2, 3 in Phase 1.

Which companies overlap with Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.'s portfolio?

Top competitors by shared drug class: GlaxoSmithKline, Institut National de la Santé Et de la Recherche Médicale, France, Assistance Publique - Hôpitaux de Paris, Green Cross Corporation, Henry M. Jackson Foundation for the Advancement of Military Medicine.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/anhui-zhifei-longcom-biologic-pharmacy-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. pipeline: 2 marketed, 0 filed, 7 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 7 Phase 3 0 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Mycobacterium Vaccae for Injection	Mycobacterium Vaccae for Injection	marketed	Immunotherapeutic vaccine		Immunology / Infectious Disease
TB-PPD was injected	TB-PPD was injected	marketed	Diagnostic antigen / Tuberculin skin test		Infectious Disease / Diagnostics
Vaccae	Vaccae	phase 3			Other
Purified Protein Derivative of Tuberculin	Purified Protein Derivative of Tuberculin	phase 3	vaccine		Immunology
Tetravalent influenza virus lysis vaccine	Tetravalent influenza virus lysis vaccine	phase 3	Inactivated influenza vaccine		Immunology / Infectious Disease
Recombinant Mycobacterium Tuberculosis Fusion Protein	Recombinant Mycobacterium Tuberculosis Fusion Protein	phase 3	Recombinant protein vaccine	Mycobacterium tuberculosis antigens (fusion construct)	Immunology / Infectious Disease
Active compared Vaccine	Active compared Vaccine	phase 3	vaccine		Immunology
BCG for Therapeutic Use	BCG for Therapeutic Use	phase 3	Live attenuated vaccine / Immunostimulant	Pattern recognition receptors (TLRs); non-specific immune activation	Oncology / Immunology
placebo of Bacillus Calmette - Guerin	placebo of Bacillus Calmette - Guerin	phase 3			Infectious Diseases

Therapeutic area mix

Immunology / Infectious Disease · 3
Immunology · 2
Infectious Disease / Diagnostics · 1
Infectious Diseases · 1
Oncology / Immunology · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 3 shared drug classes
Institut National de la Santé Et de la Recherche Médicale, France · 2 shared drug classes
Assistance Publique - Hôpitaux de Paris · 2 shared drug classes
Green Cross Corporation · 2 shared drug classes
Henry M. Jackson Foundation for the Advancement of Military Medicine · 2 shared drug classes
Il-Yang Pharm. Co., Ltd. · 2 shared drug classes
ANRS, Emerging Infectious Diseases · 2 shared drug classes
National Vaccine and Serum Institute, China · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.:

Cite this brief

Drug Landscape (2026). Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/anhui-zhifei-longcom-biologic-pharmacy-co-ltd. Accessed 2026-05-17.